SEATTLE — A Group Health study in the August 2 issue of The Lancet adds fuel to the growing controversy over how well the flu vaccine protects the elderly. The study of more than 3,500 Group Health patients age 65-plus found no link between flu vaccination and risk of pneumonia during three flu seasons. "This suggests that the flu vaccine doesn't protect seniors as much as has been thought," said Michael L. Jackson, PhD, MPH, a postdoctoral fellow at the Group Health Center for Health Studies.
"Ours is by far the largest case-control study of flu vaccine in the elderly," Jackson added. This kind of study compares "cases" with "controls." The cases were patients with "community-acquired" pneumonia treated in a hospital or elsewhere. The controls were people matched to cases by sex and age, but with no pneumonia. Both groups were found to have similar rates of flu vaccination. All had intact immune systems and none lived in a nursing home.
Jackson and his colleagues carefully reviewed medical records to reveal details of seniors' health and ability to do daily activities. "We tried to overcome the limits of previous studies done by others," he explained. "Those studies may have overestimated the benefits of the flu vaccine in the elderly for various reasons." For instance, those studies looked only at pneumonia cases treated in a hospital. They also included seniors who had immune problems, which limit potential benefit from vaccination. And they didn't review medical records to get information on chronic diseases, such as heart or lung disease, which raise the risk of pneumonia.
Most importantly, those previous studies also failed to account for differences between healthier seniors and those who were "frail," Jackson said. Frail seniors are older and have chronic diseases and difficulty walking. "They are less likely than younger, healthier seniors to go out and get vaccinated—and more apt to develop pneumonia," he said.
Pneumonia is a common and potentially life-threatening complication of the flu, Jackson said. But pneumonia can happen without the flu. "That's why our study used a control time period, after flu vaccine became available but before each flu season actually started," he said. During those pre-flu season periods, people who had been vaccinated were much less likely to get pneumonia. Why? "Because those who got the vaccine happened to be healthier—not because the flu vaccine was protecting them from pneumonia caused by the flu, since it wasn't present yet," he explained.
"Despite our findings, and even though immune responses are known to decline with age, I still want my grandmother to keep getting the flu vaccine," said Jackson. "The flu vaccine is safe. So it seems worth getting, even if it might lower the risk of pneumonia and death only slightly."
His co-author Lisa A. Jackson, MD, MPH (no relation), a senior investigator at the Group Health Center for Health Studies, agreed. "People age 65 and older should still get yearly flu vaccines as usual," she advised. But she said that researchers should work to understand better how well the current flu vaccines work in seniors—and to explore other options for controlling flu in the "old old." Examples include bigger doses or stronger types of vaccines, and conducting randomized controlled trials comparing them.
Other co-authors are Group Health's Jennifer C. Nelson, PhD and William Barlow, PhD; Noel S. Weiss, MD, DrPH of the Fred Hutchinson Cancer Research Center and University of Washington; and Kathleen M. Neuzil, MD, MPH, of the Program for Appropriate Technology in Health (PATH), University of Washington, and the Group Health Center for Health Studies, all in Seattle.
A fellowship grant from the Group Health Foundation and internal funds from the Group Health Center for Health Studies funded this study.
Source: Group Health Center for Health Studies
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.